Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to four new employees hired in July 2024. The awards include non-qualified stock options to purchase a total of 70,400 shares of Adicet's common stock at an exercise price of $1.51 per share.
The options will vest over a four-year period, with 25% vesting on the one-year anniversary of each recipient's start date, followed by monthly installments over the next three years. These awards were granted outside of Adicet's stockholder-approved equity incentive plans, using the company's 2022 Inducement Plan, as authorized by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), un'azienda biotecnologica in fase clinica focalizzata sulle terapie con cellule T gamma delta allogeniche, ha conferito premi di indennità a quattro nuovi dipendenti assunti a luglio 2024. I premi includono opzioni su azioni non qualificate per acquistare un totale di 70.400 azioni delle azioni ordinarie di Adicet a un prezzo di esercizio di $1,51 per azione.
Le opzioni acquisiranno diritto nel corso di un periodo di quattro anni, con il 25% che matura il primo anniversario della data di inizio di ciascun destinatario, seguito da rate mensili nei successivi tre anni. Questi premi sono stati concessi al di fuori dei piani di incentivazione azionaria approvati dagli azionisti di Adicet, utilizzando il Piano di Indennità 2022, così come autorizzato dal comitato per le retribuzioni in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Adicet Bio (Nasdaq: ACET), una empresa biotecnológica en etapa clínica centrada en terapias con células T gamma delta alogénicas, ha otorgado premios de inducción a cuatro nuevos empleados contratados en julio de 2024. Los premios incluyen opciones de acciones no calificadas para comprar un total de 70,400 acciones de acciones ordinarias de Adicet a un precio de ejercicio de $1.51 por acción.
Las opciones se adquirirán en un período de cuatro años, con el 25% adquiriendo derecho en el primer aniversario de la fecha de inicio de cada destinatario, seguido de cuotas mensuales durante los próximos tres años. Estos premios se otorgaron fuera de los planes de incentivos de capital aprobados por los accionistas de Adicet, utilizando el Plan de Inducción 2022, según lo autorizado por el comité de compensación de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
Adicet Bio (Nasdaq: ACET)은 동종 유래 감마 델타 T세포 치료에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 7월에 새로 고용된 네 명의 직원에게 유인 보상을 제공했습니다. 이 보상에는 Adicet의 보통주 70,400주를 주당 $1.51의 행사 가격으로 구매할 수 있는 비자격 주식 옵션이 포함됩니다.
옵션은 4년에 걸쳐 권리가 발생하며, 각 수혜자의 시작일 1주년 기념일에 25%가 발생하고, 이후 다음 3년 동안 매달 분할 지급됩니다. 이 보상은 Adicet의 주주 승인 주식 인센티브 계획 외부에서 부여되었으며, 2022 유인 계획을 사용하여 Nasdaq 상장 규정 5635(c)(4)에 따라 보상위원회에 의해 승인되었습니다.
Adicet Bio (Nasdaq: ACET), une entreprise de biotechnologie en phase clinique axée sur les thérapies avec cellules T gamma delta allogéniques, a octroyé des primes d'incitation à quatre nouveaux employés embauchés en juillet 2024. Ces primes comprennent des options sur actions non qualifiées permettant d'acheter un total de 70 400 actions d'actions ordinaires d'Adicet au prix d'exercice de 1,51 $ par action.
Les options acquerront des droits sur une période de quatre ans, avec 25 % acquérant des droits à l'anniversaire d'un an de la date de début de chaque bénéficiaire, suivi de versements mensuels pendant les trois années suivantes. Ces primes ont été accordées en dehors des plans d'incitation des actionnaires d'Adicet, en utilisant le Plan d'Incitation 2022, tel qu'autorisé par le comité de rémunération conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Adicet Bio (Nasdaq: ACET), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf allogene gamma-delta-T-Zelltherapien konzentriert, hat Anreizvergütungen für vier neue Mitarbeiter gewährt, die im Juli 2024 eingestellt wurden. Die Vergütungen umfassen nicht qualifizierte Aktienoptionen zum Erwerb von insgesamt 70.400 Aktien des Stammkapitals von Adicet zu einem Ausübungspreis von 1,51 $ pro Aktie.
Die Optionen werden über einen Zeitraum von vier Jahren erworben, wobei 25 % am ersten Jahrestag des Eintritts jedes Empfängers fällig sind, gefolgt von monatlichen Raten über die nächsten drei Jahre. Diese Vergütungen wurden außerhalb der von den Aktionären von Adicet genehmigten Aktienanreizpläne gewährt, unter Verwendung des 2022-Anreizplans, wie vom Vergütungsausschuss gemäß der Nasdaq-Notierungsregel 5635(c)(4) genehmigt.
- Adicet Bio is attracting new talent with stock option incentives
- The company is expanding its workforce with four new hires
- Stock options align employee interests with company performance
- Low stock price of $1.51 per share may indicate market challenges
- Potential dilution of existing shareholders' equity due to new stock options
Four individuals were hired by Adicet in July 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 70,400 shares of Adicet’s common stock with an exercise price of
All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731458201/en/
Adicet Bio, Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Source: Adicet Bio, Inc.
FAQ
How many new employees received stock options from Adicet Bio (ACET) in July 2024?
What is the exercise price of the stock options granted by Adicet Bio (ACET) on July 31, 2024?
How many shares of Adicet Bio (ACET) common stock can be purchased with the granted stock options?
What is the vesting schedule for the stock options granted by Adicet Bio (ACET)?
